Welcome to our dedicated page for Beyond Air news (Ticker: XAIR), a resource for investors and traders seeking the latest updates and insights on Beyond Air stock.
Beyond Air, Inc. (symbol: XAIR) is a clinical-stage medical device and biopharmaceutical company focused on revolutionizing respiratory disease treatments through innovative technology. The company's flagship product is the LungFit™ system, a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air to deliver precise amounts of NO to the lungs of both ventilated and non-ventilated patients. This breakthrough technology is aimed at treating various pulmonary diseases, including pulmonary hypertension, severe lung infections such as SARS-CoV-2, and nontuberculous mycobacteria (NTM).
LungFit™ can generate up to 400 ppm of NO, offering flexibility in delivery either continuously or for a fixed period. It also features the ability to titrate the dose on demand or maintain a constant dose. This system is currently advancing in clinical trials and has garnered attention for its potential in treating lower respiratory tract infections that are not effectively addressed by current standards of care.
Beyond Air is also exploring ultra-high concentrations of NO with a proprietary delivery system separate from LungFit™ to target certain solid tumors. This preclinical testing aims to offer new hope for cancer treatments, making Beyond Air a pioneer in utilizing NO for diverse therapeutic applications.
Notably, Beyond Air has achieved significant milestones, including FDA approval for its LungFit® PH system designed for treating term and near-term neonates with hypoxic respiratory failure. The company has partnered with The Hebrew University of Jerusalem to develop treatments for neurological disorders like autism spectrum disorder (ASD). In addition, Beyond Cancer, Ltd., an affiliate of Beyond Air, is investigating ultra-high concentrations of NO to target specific solid tumors.
Financially, Beyond Air has shown a commitment to growth, as evidenced by its recent increase in general and administrative expenses, primarily driven by stock-based compensation and professional fees. The company maintains a forward-looking stance, aiming to expand its product portfolio and enhance its market position.
For more detailed information on their latest developments and product offerings, visit Beyond Air's official website.
Beyond Air announced the appointments of Rebecca Van Doren as Head of Sales and Kori-Ann Taylor as Head of Marketing, both bringing decades of experience in the nitric oxide market.
These strategic hires aim to bolster the LungFit® PH launch in the US. Van Doren has over 20 years of experience, previously leading nitric oxide commercialization at Ikaria and Mallinckrodt, while Taylor has a robust marketing background in healthcare. Their expertise is expected to enhance sales and marketing strategies, positioning Beyond Air favorably in the competitive respiratory market as they prepare for the upcoming launch.
Beyond Air, Inc. (NASDAQ: XAIR) reported positive interim results from its ongoing pilot study using 150 ppm nitric oxide (NO) via LungFit® PRO for treating acute viral pneumonia, including COVID-19. The study showed that NO treatment was well-tolerated, with no treatment-related adverse events identified. In addition, data from three bronchiolitis pilot trials indicated a favorable safety profile and consistent efficacy. The firm is preparing for a pivotal study based on these encouraging signals supporting further development of LungFit® PRO in hospitalized patients with viral pneumonia.
Peter Senior Appointed Director of Business Development at Beyond Air
Beyond Air, Inc. (NASDAQ: XAIR) has announced the appointment of Peter Senior as Director of Business Development. Senior, with 26 years of experience at Linde plc, brings extensive knowledge in the global gas business, particularly in nitric oxide. His leadership is expected to enhance the development of the LungFit® product line, which focuses on treating respiratory conditions and solid tumors. The company aims to secure international partnerships to further advance its innovative therapeutic technologies.
Beyond Air, Inc. (NASDAQ: XAIR) has announced that CEO Steve Lisi will participate in two virtual investor conferences in May 2021. The first event is the 7th Annual Truist Securities 2021 Life Sciences Summit on May 4-5, where Lisi will engage in a fireside chat on May 4 at 11:20 AM ET. The second event is the Oppenheimer MedTech Summit on May 26, where he will be available for virtual 1-on-1 meetings. Beyond Air specializes in developing inhaled nitric oxide for respiratory conditions and is advancing its LungFit® system for treating serious lung infections.
Beyond Air, Inc. (NASDAQ: XAIR) announced its participation in the American Thoracic Society International Conference 2021, presenting two abstracts on inhaled nitric oxide. The first abstract evaluates the efficacy and safety of inhaled nitric oxide for treating acute bronchiolitis, while the second focuses on its potential in treating COVID-19 and other viral pneumonias in adults. The conference is scheduled virtually from May 14-19, 2021. Beyond Air is advancing its innovative LungFit® system, designed for delivering nitric oxide for various pulmonary conditions.
Beyond Air, Inc. (NASDAQ: XAIR) has announced that CEO Steve Lisi will participate in two virtual investor conferences in March 2021. The conferences are the 33rd Annual Roth Conference, scheduled from March 15-17, and the Oppenheimer 31st Annual Healthcare Conference on March 16-18, with Lisi presenting on March 16 at 9:20 AM ET. Beyond Air focuses on developing inhaled nitric oxide treatments for serious lung infections and pulmonary hypertension, utilizing their innovative LungFit™ system.
Beyond Air, Inc. (NASDAQ: XAIR) has secured up to $2.17 million from the Cystic Fibrosis Foundation to advance its LungFit™ GO pilot study targeting Nontuberculous Mycobacteria (NTM) pulmonary disease. This 12-week trial in Australia aims to enroll around 20 patients suffering from refractory mycobacterial lung infections. Interim data is expected mid-2021, with topline results anticipated six months later. The funding will support the self-administration of high concentration nitric oxide (NO) for improved treatment outcomes, particularly for cystic fibrosis patients.
Beyond Air (NASDAQ: XAIR) announced its FDA is reviewing the premarket approval (PMA) for LungFitTM PH to treat persistent pulmonary hypertension of the newborn (PPHN), potentially launching this summer. The company reported a revenue of $149,000 for Q3 2020, down from $314,000 in Q3 2019, with a net loss of $5.8 million, or ($0.33) per share. Their ongoing studies include acute viral pneumonia and Nontuberculous Mycobacteria treatments. Cash reserves stand at $22.7 million as of December 31, 2020. A conference call is scheduled for February 9th at 4:30 PM ET.
Beyond Air, Inc. (NASDAQ: XAIR) announces its financial results for the third fiscal quarter ending December 31, 2020. The report is scheduled for February 9, 2021, with a dedicated conference call at 4:30 PM ET. The company focuses on developing inhaled nitric oxide for various respiratory conditions and solid tumors, aiming to improve treatment options for severe lung infections like SARS-CoV-2. Beyond Air's innovative LungFit™ system delivers precise amounts of nitric oxide, targeting pulmonary diseases and advancing in clinical trials.
Beyond Air (NASDAQ: XAIR) has initiated a pilot clinical trial for its LungFit™ GO device targeting nontuberculous mycobacteria (NTM) lung disease, expected to enroll 20 adult patients in Australia. The 12-week, open-label study will first dose patients in January 2021 and report interim findings mid-2021. LungFit™ GO aims to provide at-home treatment options for patients with chronic respiratory conditions, potentially improving quality of life and outcomes for those with severe lung infections.
FAQ
What is the current stock price of Beyond Air (XAIR)?
What is the market cap of Beyond Air (XAIR)?
What is Beyond Air, Inc.?
What is the LungFit™ system?
What diseases is Beyond Air targeting with LungFit™?
What recent achievements has Beyond Air made?
What other projects is Beyond Air involved in?
How does LungFit™ generate Nitric Oxide?
What are the financial conditions of Beyond Air?
Who has Beyond Air partnered with for research?
What kind of preclinical testing is Beyond Air conducting?
Where can I get more information about Beyond Air?
